Serum Institute of India restarts manufacturing of COVID-19 vaccine Covishield
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Advertisement
New Delhi, April 12
Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday said it has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
Advertisement
He said the company already has six million booster doses of Covovax vaccine available and adults must take the booster shot.
Reacting to reports of COVID-19 vaccines shortage, he said manufacturers are ready but there has been no demand.
“Just as a precaution, at risk we have done it so that people have a Covishield as a choice if they want it,” Poonawalla told PTI on restarting of manufacturing of the vaccine.
Advertisement
The company had stopped manufacturing of Covishield in December 2021.
On Covovax which has been approved as a booster dose for 18-years and above, he said, “We have six million doses ready but the demand is exactly zero.” Covovax booster is now on the CoWin app, he said.
Advertisement
Advertisement